SCHEMBL10036016

SCHEMBL10036016

CCN1C=CC(=C/C=C2\C(=O)ON=C2c2ccccc2)C=C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 13/20 0.48
▸ MEN1 O00255 12/20 0.48
▸ MAPT P10636 8/20 0.46
▸ ALDH1A1 P00352 7/20 0.46
▸ USP2 O75604 1/20 0.46
▸ NPSR1 Q6W5P4 5/20 0.45
▸ MAPK1 P28482 3/20 0.45
▸ POLB P06746 3/20 0.45
▸ LMNA P02545 3/20 0.45
▸ PKM P14618 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ PLIN1 O60240 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ PLIN5 Q00G26 1/20 0.45
▸ ABHD5 Q8WTS1 1/20 0.45
▸ TDP1 Q9NUW8 1/20 0.45
▸ GFER P55789 1/20 0.43
▸ RECQL P46063 2/20 0.43
▸ L3MBTL1 Q9Y468 2/20 0.43
▸ GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5685863 0.86 MAPT (0.49) KMT2AMEN1MAPTALDH1A1USP2
SCHEMBL10036107 0.86 KMT2A (0.51) KMT2AMEN1MAPTALDH1A1USP2
SCHEMBL10036108 0.79 KMT2A (0.52) KMT2AMEN1MAPTALDH1A1USP2
SCHEMBL10036036 0.75 KMT2A (0.49) KMT2AMEN1MAPTALDH1A1USP2
SCHEMBL10036008 0.73 MEN1 (0.45) KMT2AMEN1MAPTALDH1A1USP2
SCHEMBL10036045 0.72 MAPT (0.47) KMT2AMEN1MAPTALDH1A1USP2
SCHEMBL12903694 0.72 KMT2A (0.61) KMT2AMEN1MAPTALDH1A1USP2
SCHEMBL10036025 0.72 KMT2A (0.54) KMT2AMEN1MAPTALDH1A1USP2
SCHEMBL10036019 0.71 MEN1 (0.55) KMT2AMEN1MAPTALDH1A1USP2
SCHEMBL13026077 0.71 MAPT (0.50) KMT2AMEN1MAPTALDH1A1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT KABUSHIKI KAISHA HAYASHIBARA SEIBUTSU KAGAKU KENKYUJO (JP) 2012-02-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120035187-A1 ANTI-NEURODEGENERATIVE DISEASE AGENT SNCA, PSEN1, CDR2 KMT2A 2624/4885MEN1 2218/4885MAPT 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback